3rd Quarter - Report

AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION for AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION

Firm
Client
Income
—
Expenses
$442,136
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Torts TOR

Advocate for legislation to enact medical liability reforms.

LobbyistCovered position, as disclosed
SHAWN FRIESEN —
KATIE JONES —
NIVA MURRAY —
CHRISTINE O'CONNOR —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act).

LobbyistCovered position, as disclosed
SHAWN FRIESEN —
KATIE JONES —
NIVA MURRAY —
CHRISTINE O'CONNOR —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 1270 (114th), S. 709 (114th), H.R. 2698 (114th)

Health Issues HCR

Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015). Support S. 1406, the Saving Access to Compounded Medications for Special Needs Patients Act. Lobby Members of Congress to join the Congressional Skin Cancer Caucus. Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, intended to protect and preserve the in-office use of compounded pharmaceuticals without a patient-specific prescription. Lobby Congress to provide oversight of implementation of Public Law 113-195, the Sunscreen Innovation Act, intended to create a transparent and predictable review process for sunscreen ingredients. Advocate for OMB to release FDA proposed rules that would provide further oversight for indoor tanning devices. Lobby Congress on issues related to telemedicine. Oppose H.R. 2519, the Audiology Patient Choice Act of 2015. Support legislation to establish a federal standard for the provision of telemedicine (H.R. 691, the Telehealth Modernization Act).

LobbyistCovered position, as disclosed
SHAWN FRIESEN —
KATIE JONES —
NIVA MURRAY —
CHRISTINE O'CONNOR —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 1600 (114th), H.R. 691 (114th), H.R. 2519 (114th), S. 1406 (114th)

Medicare/Medicaid MMM

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks. Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015). Advocate on issues related to waste, fraud and abuse in Medicare Advocate for increased funding and reforms to Graduate Medical Education. Lobby Congress on improvements to Health Information Technology implementation. Lobby Congress in opposition to repeal of the in-office ancillary and physician services exception for anatomic pathology services. Lobby Congress on issues related to telemedicine and Medicare reimbursement. Advocate on use and availability of health care data. Lobby in support of legislation to provide more flexibility in the Meaningful Use program and extend the 90 day reporting period for demonstration meaningful use in 2015 (H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act and H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act). Advocate for EHR interoperability with clinical data registries for quality improvement purposes in the 21st Century Cures Act (H.R. 6). Lobby in support of legislation to require the Secretary of Health and Human Services to issue guidance on the application of the Common Rule to clinical data registries (H.R. 965, Facilitating Participation in Clinical Data Registries Act of 2015). Support for legislation to enhance Medicare beneficiaries access to the physician of their choice (H.R. 1650, the Medicare Patient Empowerment Act). Support legislation to protect physicians and provide flexibility during the ICD-10 transition (H.R. 2126), the Cutting Costly Codes Act, (H.R. 2247), the Increasing Clarity for Doctors by Transitioning Effectively Now (ICD-TEN) Act, (H.R. 2652), the Protecting Patients and Physicians against Coding Act and (H.R. 3018), the Code FLEX Act. Advocate for changes that would improve health outcomes for Medicare patients with chronic conditions. Support legislation to improve transparency and due process in the Medicare RAC audit and appeals process (H.R. 2568, Fair Medical Audits Act). Support legislation to reduce Medicare fraud and improve access to Death Master File, S. 1073, the Stopping Improper Payments to Deceased People Act

LobbyistCovered position, as disclosed
SHAWN FRIESEN —
KATIE JONES —
NIVA MURRAY —
CHRISTINE O'CONNOR —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2568 (114th), H.R. 270 (114th), H.R. 1650 (114th), H.R. 2652 (114th), H.R. 3018 (114th), H.R. 2247 (114th), H.R. 1190 (114th), H.R. 3309 (114th), H.R. 2126 (114th), H.R. 6 (114th), H.R. 965 (114th), S. 141 (114th), S. 1073 (114th)

Medical/Disease Research/Clinical Labs MED

Support H.R. 6, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative. Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, and Food and Drug Administration (FY 16 Labor/HHS/Education Appropriations and FY 16 Agriculture Appropriations program request). Support legislation to adjust discretionary spending caps for biomedical research (S. 318/H.R. 531, Accelerating Biomedical Research Act; S. 289, American Cures Act)

LobbyistCovered position, as disclosed
SHAWN FRIESEN —
KATIE JONES —
NIVA MURRAY —
CHRISTINE O'CONNOR —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 289 (114th), H.R. 6 (114th), S. 318 (114th), H.R. 531 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.